Lucio Iannone
Biotech Investor
Lucio Iannone
Biotech Investor
Cambridge, Massachusetts
Overview
Work Experience
Head of Health Venture Investments (VP)
2021 - Current
* Identify, develop, drive and manage the portfolio of biotech ventures through to proof of concept (POC) including defining and shaping the setup of the ventures, developing the rationale and business case for investing in the selected technologies * Develop the network and follow scientific developments in selected areas * lead the venture team in deals and due diligence; * Drive and oversee the start-up of ventures and monitors/reports the progress of ventures * Train and manage junior team members * Review and make recommendations on go/no-go decision points
Sr Director of Venture Investments
2017 - 2021
• Developing rationale and business case for investing in selected technologies •Leading the sourcing, screening, and mentoring of companies with game-changing science •Conducting due diligence and supports deal execution •Supporting start-up of ventures, day-to-day management, performance management and strategic decisions of the ventures •Supporting the setup of the new organization •Monitoring progress of ventures •Supporting the venture in daily operations •Preparing and facilitating venture milestones •Establish and maintain relationships with healthcare innovators, both in entrepreneurial and academic settings
Board Member
2022
Affini-T is pioneering engineered TCR T cell therapies with cutting-edge synthetic biology and gene editing enhancements to target oncogenic driver mutations that exclusively strike all tumor cells at the core of their biology.
Board Member
2019
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.
Board Member
2022
Paratus Sciences is a start-up biotech company committed to improving human health and health security through an understanding of bat biology. We are focused on identifying and developing potential therapeutics for a myriad of diseases by unlocking the secrets of the bat genome.
Board Member
2019
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers.
Board Member
2021
Mozart is developing CD8 T cell immune modulators for the treatment of autoimmune diseases. Founded on seminal work from leading scientists, Mozart is developing biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells.
Board Member
2021
Deka has developed disease-specific Diakines™ that maximize patient benefits through improved pharmacokinetics/pharmacodynamics (PK/PD) function via targeted delivery of dual and complementary cytokines to affected tissues or cells.
Board Observer
2023
Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence
Board Observer
2022
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway
Board Observer
2022
Cellino is on a mission to make personalized, autologous cell therapies accessible for patients. Stem cell-derived regenerative medicines are poised to cure some of the toughest diseases within this decade, including Parkinson’s, diabetes, and heart disease.